Synthesizing new solutions for small molecule antibodies
Toni Rogers and David Bunka of Aptamer Group examine the latest tools and assays to address small molecule targets and deliver faster, cheaper and better diagnostics in this feature article.
The turn towards alternative affinity technologies and the use of novel selection methods will drive the acceleration of discovery and development across the life science industry, with the use of high-affinity single-reagent assays leading to a step-change in the efficiency of small molecule detection and monitoring.
Aptamer Group use a proprietary displacement method to generate single-reagent ELISA and LFD assays with positive readouts to simplify and increase the speed of diagnostic assay development for small molecule targets.
They explain how current diagnostic development is limited by high cost, slow analytical assays. Developing antibodies to hapten targets has long been challenging, stymieing progress in this field. Newer antibody alternatives such as aptamers are delivering novel solutions and simple, low cost assays that could transform healthcare with faster, point-of-care diagnostics and therapeutic drug monitoring.
Aptamer Group has recently developed a novel high-throughput selection method for its small molecule Optimers. The current success rate is in excess of 80% and the Optimers generated are showing excellent performance.